TECHNE ANNOUNCES RESIGNATION OF CHIEF FINANCIAL
                           OFFICER GREGORY MELSEN

Minneapolis, Minnesota - January 2, 2014 - Techne Corporation (NASDAQ: TECH)
today announced that Gregory J. Melsen will resign from his position as Chief
Financial Officer, effective February 3, 2014, to pursue other opportunities.
Mr. Melsen has served as Techne's Chief Financial Officer since 2004.

Techne has begun the process of identifying a successor to Mr. Melsen and
expects to announce the appointment of such successor in the coming months.

"I would like to thank Greg for his immense contributions to Techne during
the past nine years," stated Charles Kummeth, President and Chief Executive
Officer of Techne.  "Greg was instrumental in the recent leadership
transition, and the experienced financial team that Greg has put in place
will ensure that the current transition is seamless.  On behalf of Techne, I
wish Greg all the best for the future."

Mr. Melsen said, "Being Chief Financial Officer of Techne has been a great
professional experience, and I look forward to watching the Company continue
to execute the strategies that have recently been put into place."


About Techne Corporation

Techne Corporation and Subsidiaries (the Company) are engaged in the
development, manufacture and sale of biotechnology products and hematology
calibrators and controls. These activities are conducted through the
Company's two operating subsidiaries: Research and Diagnostic Systems, Inc.
(R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D
Europe) of Abingdon, England.

R&D Systems is a specialty manufacturer of biological products. R&D Systems
has four subsidiaries: BiosPacific, Inc. (BiosPacific), located in
Emeryville, California, Boston Biochem, Inc., located in Cambridge,
Massachusetts, Bionostics Holdings Limited (Bionostics), operating in Devens,
Massachusetts, and R&D Systems China Co. Ltd., (R&D China), located in
Shanghai, China. BiosPacific is a worldwide supplier of biologics to
manufacturers of in vitro diagnostic systems and immunodiagnostic kits.
Boston Biochem is a leading developer and manufacturer of ubiquitin-related
research products.  Bionostics is a leading supplier of control solutions
used in point of care blood glucose and blood gas testing.

R&D China and R&D Europe distribute the Company's biotechnology products. R&D
Europe has two subsidiaries: Tocris Holdings Ltd. (Tocris) of Bristol,
England and R&D Systems GmbH, a German sales operation. Tocris is a leading
supplier of chemical reagents for non-clinical life science research.

Forward-Looking Statements

Certain statements found in this release may constitute forward-looking
statements as defined in the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect the speaker's current views with
respect to future events and financial performance and include any statement
that does not directly relate to a current or historical fact. Forward-
looking statements can generally be identified by the words "believe,"
"expect," "anticipate" or "intend" or similar words.  The following important
factors, among others, have affected and, in the future, could affect the
Company's actual results: the integration of new leadership, the introduction
and acceptance of new biotechnology and hematology products, the levels and
particular directions of research by the Company's customers, the impact of
the growing number of producers of biotechnology research products and
related price competition, general economic conditions, the impact of
currency exchange rate fluctuations, and the costs and results of research
and product development efforts of the Company and of companies in which the
Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled
"Risk Factors" in the Company's annual report on Form 10-K and quarterly
reports on Form 10-Q as filed with the Securities and Exchange Commission. We
undertake no obligation to update or revise any forward-looking statements we
make in our press releases due to new information or future events. Investors
are cautioned not to place undue emphasis on these statements.


Contact
Charles Kummeth
Chief Executive Officer
Techne Corporation
(612) 379-8854